

## Limited Submission Funding Opportunities – updated 10/28/22

*Please be aware that any grant that brings in less than 20% in indirect costs (IDC) will need to be supplemented up to the 20% equivalent by existing investigator or departmental sundry funds. Resolution of this issue must occur prior to submitting a proposal. Training fellowships from foundations, public charity, and non-profit organizations are excluded from this minimum IDC requirement.*

*For MGH investigators selected through a competitive process as the institutional nominee for any limited submission funding opportunities, in situations in which the grant will bring in less than 20% indirect cost (IDC), ECOR will cover the IDC gap up to a maximum of \$50,000 per year. In order to optimize the distribution of limited ECOR funds across the MGH research community, it is expected that PIs and departments will work together to cover the remaining IDC shortfall.*

*This policy is only effective for those limited submission opportunities in which MGH is invited to submit its own nominee(s). This policy does not apply for those limited submission opportunities in which the MGH investigator must apply through HMS.*

*For further questions, please contact ECOR at [ecor@mgc.harvard.edu](mailto:ecor@mgc.harvard.edu)*

We ask that all MGH Investigators interested in applying for any limited submission award submit a Letter of Intent (see detailed instructions below) to the MGH Executive Committee on Research (ECOR) by the deadline indicated for each award to be considered to receive an institutional nomination.

### Process

Submit a one- to two-page Letter of Intent (LOI) to the MGH Executive Committee on Research (ECOR) via email to [ecor@mgc.harvard.edu](mailto:ecor@mgc.harvard.edu). In addition to your LOI, please include an NIH Biosketch.

The letter of intent should include:

1. *Name of the Principal Investigator with appropriate contact information*
2. *A descriptive title of the potential application*
3. *Brief description of the project*
4. *Brief description of why you specifically should be selected to receive institutional nomination for this award*

In the event that there is more than one MGH investigator interested in applying for a limited submission award, the LOIs will be used to assess candidates and a review and selection process will take place.

If there is a limited submission funding opportunity you do not see listed below or you have any additional questions, please let us know at [ecor@mgc.harvard.edu](mailto:ecor@mgc.harvard.edu).

### CURRENT OPPORTUNITIES

#### 1. **Strategically Focused Research Network (SFRN) on Biologic Pathways of Chronic Psychosocial Stressors on Cardiovascular Health (American Heart Association)**

This new Network RFA will support at least three Centers whose collective efforts will lead to a greatly enhanced understanding of mechanisms underlying the impact of chronic psychosocial stress on cardiovascular health. Each center application will include three (3) research projects from at least two (2) science disciplines. Due to the critical need for fundamental understanding of mechanisms that drive cardiovascular effects of chronic psychosocial stress, two of the proposed projects must be basic science focused.

## Limited Submission Funding Opportunities – *updated 10/28/22*

An institution may submit only one Center (and related Projects) application and only one Centralized Training Center application in response to this RFA.

### Network Center

- **Duration:** Four years
- **Award Amount:** The maximum budget amount a Center applicant may request is **\$4,433,333**.
- **IDC:** 10% of total annual expenses reported

### Letter of intent instructions

In addition to the NIH biosketch, the letter of intent (2-3 pages) should include:

1. *Name of the Center Director with appropriate contact information*
2. *A descriptive title of the potential application*
3. *Indicate whether your application is a Center application or a Centralized Training Center application*
4. *List of participating principal investigators*
5. *Brief description of your Center. Be sure to state the specific aims of your Center, followed by a list of the Projects that will be submitted with the Center application.*
6. *Brief description of why you specifically should be selected to receive the institutional nomination for this award*

### **MGH LOI Deadline: 11/02/22**

Sponsor required pre-proposal deadline: 11/17/22

Sponsor Application Deadline: 1/19/23

[Learn more](#)

## **2. Postbaccalaureate Research Education Program (PREP) (R25 – Independent Clinical Trial Not Allowed)**

The NIH Research Education Program (R25) supports research education activities in the mission areas of the NIH. The overarching goal of this R25 program is to support educational activities that encourage individuals from diverse backgrounds, including those from groups underrepresented in the biomedical and behavioral sciences, to pursue further studies or careers in research.

To accomplish the stated over-arching goal, this FOA will support creative educational activities with a primary focus on:

- ***Courses for Skills Development***
- ***Research Experiences***

This Funding Opportunity Announcement (FOA) provides support to eligible, domestic institutions to develop and implement effective, evidence-informed approaches to biomedical research education and mentoring that will keep pace with the rapid evolution of the research enterprise. NIGMS expects that the proposed research education programs will incorporate extensive research experiences and well-designed courses for skills development to prepare recent baccalaureates from diverse backgrounds to transition into and complete rigorous, research-focused biomedical doctoral degree programs (e.g., Ph.D. or M.D./Ph.D.). This program is limited to applications from doctoral degree-granting institutions that are research-intensive (i.e., those with NIH research project grant (RPG) funding averaging greater than or equal to \$7.5 million in total costs per year over the last three fiscal years).

This FOA does not allow appointed participants to lead an independent clinical trial but does allow them to obtain research experience in a clinical trial led by a mentor or co-mentor.

## Limited Submission Funding Opportunities – updated 10/28/22

**MGH LOI Deadline: 11/08/22**

NIH Application Deadline: 1/31/23

[Learn more](#)

### 3. NCI Pathway to Independence Award for Outstanding Early Stage Postdoctoral Researchers (K99/R00 – Independent Clinical Trial Not Allowed)

The purpose of the NCI Pathway to Independence Award for Outstanding Early Stage Postdoctoral Researchers (K99/R00) program is to increase and maintain a strong cohort of new and talented, NCI-supported, independent investigators. This program is designed for postdoctoral fellows with research and/or clinical doctoral degrees who do not require an extended period of mentored research training beyond their doctoral degrees. The objective of this award is to facilitate a timely transition of these fellows from their mentored, postdoctoral research positions to independent tenure-track (or equivalent) faculty positions. The program will provide independent NCI research support during this transition to help awardees to launch competitive, independent research careers. Researchers in the scientific areas of data science and cancer control science are especially encouraged to work with their institutions to apply.

*This Funding Opportunity Announcement (FOA) is designed specifically for candidates proposing research that does not involve leading an independent clinical trial, a clinical trial feasibility study, or an ancillary clinical trial. Under this FOA candidates are permitted to propose a research experience in a clinical trial led by a mentor or co-mentor. Those proposing a clinical trial or an ancillary clinical trial as lead investigator, should apply to the companion FOAs ([RFA-CA-22-036](#) or [RFA-CA-22-037](#))*

Each eligible institution may submit up to a combined total of three applications (one in Data Science, one in Cancer Control Science, and one in Other Sciences) to any companion RFA or any combination of companion RFAs ([RFA-CA-22-035](#), [RFA-CA-22-036](#), and/or [RFA-CA-22-037](#)). In your letter of intent, please indicate which are you are submitting under: **Data Science, Cancer Control Science, or Other Sciences.**

**MGH LOI Deadline: 12/15/22**

NIH Application Deadline: 2/28/23

[Learn more](#)

### 4. NCI Pathway to Independence Award for Outstanding Early Stage Postdoctoral Researchers (K99/R00 – Independent Clinical Trial Required)

The purpose of the NCI Pathway to Independence Award for Outstanding Early Stage Postdoctoral Researchers (K99/R00) program is to increase and maintain a strong cohort of new and talented, NCI-supported, independent investigators. This program is designed for postdoctoral fellows with research and/or clinical doctoral degrees who do not require an extended period of mentored research training beyond their doctoral degrees. The objective of this award is to facilitate a timely transition of these fellows from their mentored, postdoctoral research positions to independent tenure-track (or equivalent) faculty positions. The program will provide independent NCI research support during this transition to help awardees launch competitive, independent research careers. Researchers in the scientific areas of data science and cancer control science are especially encouraged to work with their institutions to apply. This Funding Opportunity Announcement (FOA) is designed specifically for candidates proposing to serve as the lead investigator of an independent clinical trial, a clinical trial feasibility study, or a separate

## Limited Submission Funding Opportunities – *updated 10/28/22*

ancillary clinical trial, as part of their research and career development. Those not planning an independent clinical trial, or proposing to gain research experience in a clinical trial led by another investigator, must apply to companion FOA ([RFA-CA-22-035](#)).

Each eligible institution may submit up to a combined total of three applications (one in Data Science, one in Cancer Control Science, and one in Other Sciences) to any companion RFA or any combination of companion RFAs ([RFA-CA-22-035](#), [RFA-CA-22-036](#), and/or [RFA-CA-22-037](#)). In your letter of intent, please indicate which are you are submitting under: **Data Science, Cancer Control Science, or Other Sciences.**

**MGH LOI Deadline: 12/15/22**

NIH Application Deadline: 2/28/23

[Learn more](#)

### 5. NCI Pathway to Independence Award for Outstanding Early Stage Postdoctoral Researchers (K99/R00 – Independent Basic Experimental Studies with Humans Required)

The purpose of the NCI Pathway to Independence Award for Outstanding Early Stage Postdoctoral Researchers (K99/R00) program is to increase and maintain a strong cohort of new and talented, NCI-supported, independent investigators. This program is designed for postdoctoral fellows with research and/or clinical doctoral degrees who do not require an extended period of mentored research training beyond their doctoral degrees. The objective of this award is to facilitate a timely transition of these fellows from their mentored, postdoctoral research positions to independent tenure-track (or equivalent) faculty positions. The program will provide independent NCI research support during this transition to help awardees launch competitive, independent research careers. Researchers in the scientific areas of data science and cancer control science are especially encouraged to work with their institutions to apply.

This Funding Opportunity Announcement (FOA) is designed specifically for candidates proposing to serve as the lead investigator of an independent clinical trial, a clinical trial feasibility study, or a separate ancillary clinical trial, as part of their research and career development. Those not planning an independent clinical trial, or proposing to gain research experience in a clinical trial led by another investigator, must apply to companion FOA ([RFA-CA-22-035](#)).

This Funding Opportunity Announcement is for basic science experimental studies involving humans, referred to in [NOT-OD-18-212](#) as “prospective basic science studies involving human participants.” These studies fall within the NIH definition of a clinical trial and also meet the definition of basic research. Types of studies that should be submitted under this FOA include studies that prospectively assign human participants to conditions (i.e., experimentally manipulate independent variables) and that assess biomedical or behavioral outcomes in humans for the purpose of understanding the fundamental aspects of phenomena without specific application towards processes or products in mind. Applicants not planning an independent clinical trial or basic experimental study with humans, or proposing to gain research experience in a clinical trial or basic experimental study with humans led by another investigator, must apply to the 'Independent Clinical Trial Not Allowed' companion FOA.

The proposed project must be related to the programmatic interests of one or more of the participating NIH Institutes and Centers (ICs) based on their scientific missions.

Each eligible institution may submit up to a combined total of three applications (one in Data Science, one in Cancer Control Science, and one in Other Sciences) to any companion RFA or any combination of

## Limited Submission Funding Opportunities – *updated 10/28/22*

companion RFAs ([RFA-CA-22-035](#), [RFA-CA-22-036](#), and/or [RFA-CA-22-037](#)). In your letter of intent, please indicate which are you are submitting under: **Data Science, Cancer Control Science, or Other Sciences.**

**MGH LOI Deadline: 12/15/22**

NIH Application Deadline: 2/28/23

[Learn more](#)